TwoStep Therapeutics is a biotechnology company specializing in tumor-targeting therapies. It utilizes a proprietary Polyspecific Integrin-binding Peptide (PIP) technology to deliver therapeutic payloads specifically to solid tumors, aiming to enhance the efficacy and safety of cancer treatments.

TwoStep Therapeutics is pioneering a multi-targeting platform to advance a pipeline of targeted therapies that are broadly applicable across solid tumors. With this approach, the company aims to transform cancer treatment by extending precision medicines to more diverse tumor types and patient populations, for which few options exist. TwoStep Therapeutics was co-founded by CEO, Caitlyn Miller, in collaboration with world-renowned academic entrepreneurs at Stanford University: Jennifer Cochran, Ronald Levy, and Nobel Laureate Carolyn Bertozzi. For more information, visit www.twosteptx.com.  

TwoStep Therapeutics

Our co-founder and CEO Caitlyn Miller, PhD spoke with Kyle LaHucik at Endpoints News about our work developing a novel tumor-targeting platform for solid tumors - and how the broad applicability of this approach opens up new possibilities for cancer treatment.

Read more in Endpoints News👇 
https://lnkd.in/gx_4paV3

We’re excited to announce our official launch and the closing of a $6.5M seed round to advance our pipeline of targeted therapies for solid tumors.

Our delivery platform is built around a unique tumor-targeting agent that can selectively bind five targets that are highly expressed on solid tumors. This multi-targeting feature enables broad applicability across a wide range of tumor types and patient populations, overcoming the limitations of traditional single-antigen targeting approaches. 

Led by co-founder and CEO Caitlyn Miller, PhD, our mission is to revolutionize cancer care by developing precise, effective, and broadly applicable targeted therapies.

Our work is guided by world-class academic-entrepreneurs at Stanford, including co-founders Carolyn Bertozzi, Jennifer Cochran and Ron Levy.

We launched from the Stanford University Innovative Medicines Accelerator (IMA) and are backed by a syndicate of high quality investors, led by NFX with participation from 2048 Ventures, Alexandria Real Estate Equities, Inc., Cooley LLP’s affiliated fund GC&H Investments, and the family office of the founder of Arcadia Investment Partners. 

Read the full press release to learn more: 
Press Release: https://lnkd.in/gErBpaBg
Endpoints article: https://lnkd.in/gx_4paV3
Company website: www.twosteptx.com

COM:TWOSTEPTX

TwoStep Therapeutics

Analysis Not Available